Table 2.
Mean calibrated TBS percentage change from baseline: TBSBMI vs TBSTT
| TBSBMI, LS mean (95% CI) | TBSTT, LS mean (95% CI) | |||||
|---|---|---|---|---|---|---|
| n | % change from baseline | Difference from placebo | n | % change from baseline | Difference from placebo | |
| Month 1 | ||||||
| Placebo | 122 | 0.20 (− 0.50, 0.90) | − 0.45 (− 1.41, 0.51) | 121 | 0.06 (− 0.74, 0.86) | 0.30 (− 0.79, 1.40) |
| Denosumab | 140 | − 0.25 (− 0.91, 0.40) | 138 | 0.36 (− 0.38, 1.11) | ||
| Month 12 | ||||||
| Placebo | 122 | − 0.32 (− 1.02, 0.39) | 1.68* (0.73, 2.64) | 121 | − 0.60 (− 1.39, 0.20) | 2.90** (1.81, 3.99) |
| Denosumab | 142 | 1.37† (0.72, 2.02) | 141 | 2.31† (1.57, 3.05) | ||
| Month 24 | ||||||
| Placebo | 125 | − 0.28 (− 0.98, 0.42) | 1.76* (0.81, 2.71) | 124 | − 0.31 (− 1.10, 0.48) | 2.94** (1.85, 4.02) |
| Denosumab | 143 | 1.48† (0.83, 2.13) | 141 | 2.63† (1.89, 3.37) | ||
| Month 36 | ||||||
| Placebo | 123 | − 1.07 (− 1.76, − 0.37) | 2.91** (1.96, 3.87) | 123 | − 1.38 (− 2.17, − 0.58) | 4.67** (3.59, 5.76) |
| Denosumab | 143 | 1.85† (1.20, 2.50) | 141 | 3.29† (2.55, 4.04) | ||
n = number of subjects with observed data. *p < 0.001 compared with placebo; **p < 0.0001 compared with placebo; †p < 0.0001 compared with baseline; CI confidence interval; LS least squares; TBS trabecular bone score; TBSBMI BMI-adjusted TBS; TBSTT tissue thickness–adjusted TBS